The bankruptcy underscores the great risks of investing in many of the companies that have gone public via mergers with special-purpose acquisition corporations.

Bankrupt genetic test company 23andMe may face opposition from the U.S. government if it tries to sell itself to a foreign ...

Following biotechnology company 23andMe's filing for bankruptcy, losing its CEO, and trying to find a buyer last month, the ...

Me on Sunday filed for bankruptcy in the U.S. after struggling with weak demand for its ancestry testing kits and a 2023 data ...

Leaders of the House Committee on Energy and Commerce said they are investigating how 23andMe’s bankruptcy might affect ...

But since 23andMe is not a medical provider it does not have to abide by standard privacy policies that must be followed at a doctor's office. Such services are "not regulated well," said Ayday.

Genetic analysis company 23andMe (ME) announced this week it's declaring bankruptcy and pursuing a sale, leading many customers to pursue deleting their data from the company. 23andMe was founded ...

Just before the 23andMe SPAC deal closed ... giving investors the impression it is a risk-free investment. Some companies do not find appropriate acquisition targets and have to redeem the ...

23andMe bankruptcy underscores the risk of investing in most SPACs. - MarketWatch photo illustration/iStockphoto 23andMe is going bankrupt — underscoring the great ...

Just before the 23andMe SPAC deal closed ... giving investors the impression it is a risk-free investment. Some companies do not find appropriate acquisition targets and have to redeem the ...